Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002962 (angina)
 21,142 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An intravenous preparation of doxycycline (DOTC, Vibramycin 'Pfizer'), a long-lasting tetracycline, was administered mainly by drip infusion for a series of study in the pediatrics field, and the results were as follows: 1) DOTC (100 mg) was dissolved in a 100 ml of glucose solution and 2--3 mg/kg was administered intravenously. When the total infusion time was adjusted between one to two hours, the peak serum level of DOTC was seen at the end of infusion in each case. The serum level in a two-hour infusion time, however, the serum level was delectable for a long period of time: the serum level after 10 hours was 0.82--1.23 micrograms/ml. Above results suggest that DOTC intravenous should be given in a two-hour infusion twice a day for applicable infections in the pediatrics field. 2) Urine excretion of DOTC was about a half (50%) of the administered dosage. 3) DOTC was given mostly at about 3--5 mg/kg per day (twice a day) infusion to 25 children with five infections, viz. acute angina lacunaris, acute bronchitis, bronchopneumonia, Mycoplasma pneumonia and acute urinary tract infections. A clinical improvement seemed attributable to DOTC was clearly observed in 23 out of 25 patients (92%). 4). DOTC infusion was also effective for Mycoplasma meningoencephalitis, severe Mycoplasma pneumonia associated with pleuritis, bronchitis and bronchopneumonia with a lot of Staphylococcus aureus identified in the sputum medium, acute urinary tract infections caused by E. coli. 5) Before and ten days after DOTC infusion, laboratory tests for liver and renal functions and blood were performed. No noticeable abnormalities were found except one case with transient GOT and GPT elevations. Above summary was presented at the 26th annual meeting of Japan Society of Chemotherapy in June 1978.
 ...
PMID:[A clinical study of intravenous doxycycline in the pediatrics field (author's transl)]. 51 84

Laboratory and clinical studies were performed on a new semisynthetic cephalosporin, cefamandole (CMD), and following results were obtained. (1) Serum concentrations and urinary recovery rates of CMD were determined after an intravenous administration of CMD 30 mg/kg in 13 children with normal renal function. In 5 of 13 children, mean serum levels after a one shot intravenous injection were 112.5 micrograms/ml at 15 minutes, 52.2 micrograms/ml at 30 minutes, 23.3 micrograms/ml at 1 hour, 4.9 micrograms/ml at 2 hours and trace at 4 hours. In other 5 children, mean serum levels after drip infusion for 1 hour were 78 micrograms/ml at 30 minutes, 59 micrograms/ml at 1 hour, 9.8 micrograms/ml at 2 hours and trace at 4 hours, after the onset of drip infusion. In the remaining 3 children who received CMD by drip infusion for 2 hours, mean serum levels were 24.3 micrograms/ml at 30 minutes, 35.3 micrograms/ml at 1 hour, 30.2 micrograms/ml at 2 hours, 5.3 micrograms/ml at 3 hours and 1.5 micrograms/ml at 4 hours after the onset of drip infusion. Urinary recovery rates in 5 children were 154.7%, 98.3%, 93.2%, 111.8% and 66.9%, respectively, during 8 hours. (2) CMD was administered to 40 patients with various infections (acute U.T.I. 8, acute angina lacunaris; 2, acute bronchitis; 5, cervical purulent lymphadenitis; 2, post-measles bronchopneumonia; 3, acute bronchopneumonia; 18, pyothorax; 2, S.S.S. syndrome; 1) by one-shot intravenous injection at a dose of 40-120 mg/kg per day. The clinical efficacy rate was 92.5% and bacteriological efficacy rate was 79.2%. (3) As the side effect of CMD, eosinophilia was observed in 1 case, rash and elevation of GOT and GPT in 1 case, and proteinuria in 1 case.
 ...
PMID:[Laboratory and clinical studies on cefamandole in pediatric field (author's transl)]. 51 91

In the preceding articles a preventive screening model in two factories was described, the results were given and the exactitude of laboratory tests presented. In this paper the relations are studied between all the observed variables. Contingency-tables and the x2-statistic are used. For the 57 observed variables-(laboratory variables, e.g. triglicerides, cholesterol, glucose, uric acid, creatinine and questionnaire-items designed to screen for angina pectoris, myocardial infarction, claudicatio intermittens and bronchitis)-all possible contingency tables between two variables were calculated (1596 tables). The significant connections are reported in form of a hypothesis-matrix. There exists no statistical correlation between laboratory tests and questionnaire-items. The anamnestic questionnaire cannot be replaced by laboratory tests and vice versa. Nearly all items of the questionnaire are correlated. There are some correlations between laboratory tests, blood pressure and smoking habits.
 ...
PMID:[Preventive screening in two factories. III. Relations between quantitative variables and questionnaire-items (author's transl)]. 100 77

19 consecutive patients (18 men, one woman, mean age 61.4 [49-73]years) with chronic obstructive airways disease (bronchitis and emphysema) together with angiographically confirmed coronary heart disease were studied to investigate their cardiopulmonary exercise tolerance and the effects of bronchodilators on their myocardial ischaemia. Because they were receiving drug therapy for angina or because they had previously undergone aortocoronary bypass operation or balloon dilatation, the patients were symptom-free. In three cases slight ischaemia was demonstrable during maximal exertion. Aerobic and anaerobic exercise capacity was determined by spiroergometry after inhalation of salbutamol (S, 0.2 mg) alone or in combination with oxitropium bromide (O, 0.2 mg). The supplementary effect of oral theophylline (T, 15 mg/kg.day) was studied in 13 patients. In terms of maximal aerobic exercise tolerance the following improvements were noted: energy output (watts): S: + 6.3%; S and O: + 12.3% (P < 0.05); S, O and T: + 14.0% (P < 0.01). Oxygen uptake (ml/min): S: + 8.2% (P < 0.05); S and O: + 18.2% (P < 0.01); S, O and T: + 35.4% (P < 0.01). Maximum exercise capacity was not significantly improved, although maximum oxygen uptake was significantly increased by the two-drug combination by 16.9% (P < 0.05) and by the three-drug combination by 19.2% (P < 0.05). Maximum minute volume and tidal volume rose significantly, though respiratory rate was unchanged. Heart rate and blood pressure remained practically unaffected by the treatment, both at rest and during exertion. There was no evidence of significant aggravation of ventricular arrhythmias or of ischaemia during ergometric testing.
 ...
PMID:[Physical exercise tolerance in chronic obstructive emphysematous bronchitis and coronary heart disease under antiobstructive therapy]. 142 60

A study of the immune and fibrinolytic systems of the body in 216 patients with different clinical forms of atherosclerosis (exertion and rest stenocardia, arrhythmias, atherosclerotic hypertension), chronic obstructive bronchitis revealed that the antiatherogenous effect of chronic obstructive bronchitis is predetermined on the one side by an increased function of the monocytic-macrophagal link of immunity and on the other by activation of the fibrinolysis system.
 ...
PMID:[The role of the immune and fibrinolytic systems in the inhibition of atherogenesis in chronic obstructive bronchitis]. 144 83

Immunological indices were compared in 138 patients with angina and concomitant bronchitis; 86 of them received antibiotics, splenin and vylosen; 52 received routine treatment. It was established that use of a combination of splenin and vylosen produces a pronounced immunodulating effect in primary immunodeficiency states due to recurrences of angina and concomitant pathology of the bronchopulmonary in workers of a large industrial enterprise. Immunomodulators are indicated in the treatment of repeat and relapsing angina, especially in the presence of concomitant bronchitis.
 ...
PMID:[The immunomodulating action of vilozen and splenin in angina patients against a background of chronic bronchitis]. 147 36

The authors propose a new approach to evaluation of biochemical indices in internal organ diseases, namely, comparison of factually detectable results with individual initial data. It was established that in stenocardia the majority of patients showed an increase of activity of cardio-specific enzymes. Patients with exacerbation of obstructive bronchitis revealed diverse changes of the content of immunoglobulins, complement components and proteinase inhibitors. The authors suggest that an individual approach to comparison of laboratory indices reflects more precisely the response of the patient's body to the pathological process.
 ...
PMID:[A new approach to assessing the blood biochemical indices in diseases of the internal organs]. 175 31

A cohort comparison between two different populations of 70 year-olds in Glostrup who had health examinations in 1967 (230 men and 210 women) and in 1984 (412 men and 392 women) was conducted with the purpose of describing changes in health variables among old people during a period of falling mortality for both men and women. From the 1967 investigation to the 1984 investigation there was a significant improvement of the cardiovascular risk profile (i.e. body mass index, blood pressure, serum cholesterol, glucose tolerance) which is consistent with other such investigations. In contrast to these findings, symptoms of chronic conditions (angina pectoris, intermittent claudication and bronchitis) as well as the need for health care were the same in the two populations of 70 year-olds. In addition, the 1914 cohort reported a more pessimistic outlook with regard to their general health and greater consumption of medicine. The results of this investigation are consistent with expectations regarding changes in risk factors and mortality in older generations. The consequences of the falling mortality for morbidity and functional ability in a life perspective are, however, still uncertain, and cannot be evaluated alone from results such as these.
 ...
PMID:[Health status of the 70-year-old population in the past and present. A cohort comparison of 70-year old men and women born in 1987 and 1914 in Glostrup]. 223 67

In an open study with 16 angina pectoris patients with concomitant chronic obstructive bronchitis, the effect of single oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30, and 40 mg) on blood pressure (BP), heart rate (HR), airway resistance (AWR), and forced expiratory volume in 1 s (FEV1) was investigated. In the dose range between 5 and 20 mg, no increase in AWR and no decrease in FEV1 was observed. Thirty and 40 mg of bisoprolol produced an increase in AWR and a decrease in FEV1. A reduction in BP and HR was observed even after the lowest bisoprolol dose.
 ...
PMID:Beta 1/beta 2-splitting of bisoprolol. 243 1

The primary goals in the management of hypertension, angina pectoris, and postinfarction cases are to prevent further damage to the cardiovascular system and to reduce the risk of subsequent myocardial infarction. Of all the drugs currently available, the beta-blockers seem the most likely to achieve this aim. The search for new beta-blockers centers around the need for agents that offer the advantages of beta 1-adrenoceptor antagonism without the unwanted beta 2 effects, which may be dangerous in asthmatic patients and may make bronchitis, diabetes, and arteriopathy worse or more difficult to control. One solution is to use a selective beta 1-adrenoceptor antagonist. Another is to develop a molecule that acts as an antagonist at beta 1-adrenoceptors and as an agonist at beta 2-adrenoceptors. celiprolol is such a "third-generation" beta-blocker in that it combines both attributes, and thereby offers a clinically relevant advance. It does not seem to disrupt glucose homeostasis or exacerbate peripheral vascular disease, the lipid profile appears to be positively altered, and the risk of bronchospasm is reduced. Celiprolol is therefore both clinically and biochemically well tolerated.
 ...
PMID:Pharmacology of third-generation beta-blockers: greater benefits, fewer risks. 248 89


1 2 3 4 Next >>